The burden of out-of-pocket and indirect costs of prostate cancer

Prostate

Volumn 70, Issue 11, 2010, Pages 1255-1264

  Jayadevappa, Ravishankar ^a   Schwartz, J Sanford ^a,b   Chhatre, Sumedha ^a   Gallo, Joseph J ^a   Wein, Alan J ^a   Malkowicz, S Bruce ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cost of illness; External beam radiation therapy; Health related quality of life; Indirect cost; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE;

AGED; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH STATUS; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; UNITED STATES;

EID: 77956027853     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21161     Document Type: Article

References (28)

1. Jemal A, Siegal R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Penson DF, Chan JM. Prostate Cancer. In: Saigal MS, Saigal CS, editors. Urologic diseases in American, Chapter 3. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office; NIH Publication No. 07-05512. 2007.
3. Kim P. Cost of cancer care: The patient perspective. J Clin Oncol 2007;25(2):228-232.
4. Liu L, Rettenmaier AJ, Saving TR. Indirect costs and discounting in health care decision-making: The role of distortionary taxation. Contrib Econ Anal Policy 2006;5(1):1-28.
5. Sulmasy DP. Cancer care, money, and the value of life: Whose justice? Which rationality? J Clin Oncol 2007;25(2):217-222.
6. Fryback DG, Criag BM. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr 2004;33:134-141.
7. Ya-Chen Tina Shih, Halpern MT. Economic evaluations of medical care interventions for cancer patients: How, why and what does it mean? CA Cancer J Clin 2008;58:231-244.
8. Shireman TL, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Int J Technol Assess Health Care 2001;17:146-152.
9. Schulpher M, Palmer MK, Heyer A. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics 2000;17:361-370.
10. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd edition, Oxford: Oxford University Press; 1997.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
12. Barnett PG. Review of methods to determine VA-health care costs. Med Care 1999;37(4):AS9-AS17.
13. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA prostate cancer index: Development, reliability, and validity of health-related quality of life measure. Med Care 1998;36:1002-1012. (Pubitemid 128456439)
14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-for health survey (SF-36)-conceptual framework and item selection. Med Care 1992;30:473-483.
15. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
16. Greene WH. Econometric analysis, 4th edition. Upper Saddle River, New Jersey: Prentice Hall; 2000.
17. Allison PD. Logistic regression using the SAS system: Theory and application. Cary, NC: SAS Institute, Inc.; 1999.
18. Oakes M. Statistical inference. Chestnut Hill, MA: Epidemiological Resources; 1990.
19. Engels JM, Diehr P. Imputation of missing longitudinal data: A comparison of methods. J Clin Epidemiol 2003;56:968-976.
20. Meropal NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007;25(2):180-186.
21. Sach TH, Whynes DK. Measuring indirect costs: Is there a problem. Appl Health Econ Health Policy 2003;2(3):135-139.
22. Glied S. Estimating the indirect cost of illness: An assessment of the forgone earnings approach. Am J Public Health 1996;86(12):1723-1728. (Pubitemid 27045296)
23. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature - A review. Int J Technol Assess Health Care 1998;14(4):799-808.
24. McKoy JM, Fitzner KA, Edwards BJ, Alkhatib M, Tigue CC, Nonzee NJ, Bolden CR, Bennett CL. Cost considerations in management of cancer in the older patients. Oncology 2007;21(7):21-27.
25. Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ 1994;3(6):385-393.
26. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of prostate cancer, California, 1998. Cancer 2002;94:2906-2911.
27. Matchar DB, McCrory DC, Bennett CL. Treatment considerations for persons with metastatic prostate cancer: Survival versus out-of-pocket costs. Urology 1997;49:218-224.
28. Bradley CJ, Neumark D, Luo Z, Bednarek H, Schenk M. Employment outcomes of men treated for prostate cancer. J Natl Cancer Inst 2005;97:958-967.